Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Literature
1.
Lebbé C, Meyer N, Mortier L et al (2019) Evaluation of two dosing regimens for Nivolumab in combination With Ipilimumab in patients with advanced melanoma: results from the phase IIIb/IV CheckMate 511 Trial. J Clin Oncol 37(11):867–875CrossRef
2.
Haanen JBAG, Carbonnel F, Robert C et al (2017) Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl 4):i119–i142CrossRef
3.
Bourgeois S, Van Den Berghe I, De Geeter F (2016) Incidental finding of silent appendicitis on (18)F-FDG PET/CT in a patient with small cell lung adenocarcinoma. Hell J Nucl Med 19(2):164–166PubMed
4.
Leipe J, Christ CA, Arnoldi AP et al (2018) Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy. RMD Open 4:e000714CrossRef
5.
Simonaggio A, Michot JM, Voisin AL et al (2019) Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol 5(9):1310–1317CrossRef
Metadata
Title
Silent acute appendicitis revealed by PET-CT during treatment with ipilimumab and nivolumab: a new immune-related adverse event
Authors
C. Mangas
S. Leoni-Parvex
V. Spataro
Publication date
01-11-2020
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 11/2020
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-020-02724-3

Other articles of this Issue 11/2020

Cancer Immunology, Immunotherapy 11/2020 Go to the issue

Research Report

Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer

Original Article

Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer

Original Article

Differences in PD-1 expression on CD8+ T-cells in chronic myeloid leukemia patients according to disease phase and TKI medication

Original Article

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%

Original Article

Cell composition and expansion strategy can reduce the beneficial effect of AKT-inhibition on functionality of CD8+ T cells

Original Article

Clinicopathological factors associated with tumor-infiltrating lymphocyte reactivity in breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits